All News

Enjoy a refreshing kale salad on a sunny afternoon and a savory chickpea curry during an April shower. And don’t forget to treat yourself with kindness — and pudding!

A wife pens a letter to her husband on the first anniversary of his death from cancer about all the things he’s missed — from the big dates to the boring days, such as just watching TV with their dog.

In an interview with CURE®, Ireland shared details on how to get involved in the "43 challenge" and offered some advice to families who may find themselves impacted by pediatric cancer.

Ayvakit demonstrated more durable survival outcomes in patients with unresectable/metastatic platelet-derived growth factor receptor A D842V-mutant gastrointestinal stromal tumors than tyrosine kinase inhibitors.

How one survivor’s journey led to her realization of what survivorship care is lacking and the importance of advocating for yourself during survivorship.

The FDA has approved the combination of Opdivo (nivolumab) plus certain types of chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma, making it the first frontline immunotherapy agent approved in this space.

A cancer survivor and former military service member writes how he used to be short with people, demanded things be done his way and often made others feel little — that is until his cancer diagnosis. Here, he shares how his experience with cancer taught him to be kinder to others.

From a 5-year-old with brain cancer celebrating his final round of radiation at a hockey game to a cancer diagnosis for Exodus drummer Tom Hunting, here’s what’s happening in the cancer landscape this week.

The FDA has recommended the manufacturer of a cell-based immunotherapy terminate a phase 2 clinical trial assessing its effectiveness in recurrent or progressive glioblastoma early and pursue a phase 3 trial which may lead to an approval.

A recent data review found that dietary patterns such as higher intakes of dietary fiber, calcium and yogurt and lower intakes of red meat and alcohol may lower the risk of colorectal cancer.

Navigating medical leave and insurance forms can be nerve-wracking and feel high stakes for some, writes a cancer survivor. Here, he offers advice on how to manage that stress.

In this episode of the “CURE® Talks Cancer” podcast, Pamela Hegg details her journey with a rare form of endometrial cancer and explains how she’s able to stay positive through multiple recurrences.

Antibiotics, corticosteroids and proton pump inhibitors could cause negative impacts on survival in patients with non-small cell lung cancer who are receiving treatment with Keytruda.

A slower walking pace may be associated with a higher risk of mortality rate in survivors of cancer compared with their healthy matched peers, according to an expert.

Recent study results demonstrated an possible association between a high BMI and risk of cancer and overall mortality, though patients with obesity and lung cancer, renal cell carcinoma and melanoma were found to have a lower risk of death than patients with the same cancers without obesity.

No matter how far you think you’ve gotten away from them, cancer’s side effects are always in your rear-view mirror, writes this caregiver.

A study out of Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University in Philadelphia found that 87% of survivors of breast, pelvic, endometrial, prostate, bladder and rectal cancer said treatment affected their sexual function or desire.

Reintroducing treatment with Jakafi in patients with myelofibrosis after previous discontinuation extended overall survival compared to those patients who stopped permanently, although there was a substantial rate of permanent treatment discontinuation with this therapy.

Several factors were associated with patients undergoing radical nephrectomy compared with radical nephroureterectomy including Black race, large tumors, advanced tumor stage and high-grade tumors.

Trodelvy has received accelerated approval from the FDA for the treatment of patients with advanced urothelial cancer.

On Feb. 18, CURE hosted a webinar focused on educating patients on biomarker testing. Here, we highlight key takeaways from our panelists.

An oncology nurse recalls how a young patient with Ewing sarcoma she helped care for taught her about bravery and being honest with patients. Here, she writes how he made her a better nurse.

A 500 mg dose of Tepmetko, a MET inhibitor, in patients with hepatocellular carcinoma who were previously treated with Nexavar led to a 12-week progression-free survival rate of 63.3%.

On behalf of the National Ovarian Cancer Coalition, CURE spoke with Dr. Debra Richardson, from Stevenson Cancer Center, about the basics of ovarian cancer and its treatments, clinical trials and psychosocial effects.

Adjusting the dose of cisplatin, when added to regular doses of Abraxane and gemcitabine, led to similar survival rates when treating patients with advanced/metastatic urothelial carcinoma, which may help to address issues commonly seen with patients who cannot tolerate cisplatin such as renal dysfunction.

On social media, CURE® recently asked its readers to share where they first turned to for information after they received their cancer diagnosis. Here’s what some of them said.

Mesothelioma has been categorized as an “older persons” disease, writes a 14-year survivor. Which is why, she writes, her and her family were completely caught off-guard when she was diagnosed at 21.

In an interview, Dr. Nina Shah of UCSF Helen Diller Family Comprehensive Cancer Center discusses how she changed her perspective on finding a cure for myeloma and what her goals are when it comes to treating her patients.